trending Market Intelligence /marketintelligence/en/news-insights/trending/4VlyuT2usViqGbcMqYC__g2 content esgSubNav
In This List

Hutchison China MediTech seeks regulatory approval for cancer drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Hutchison China MediTech seeks regulatory approval for cancer drug

Hutchison China MediTech Ltd. filed an application with the China Food and Drug Administration, seeking approval for fruquintinib in patients with advanced colorectal cancer.

The application is supported by data from a successful phase 3 trial.

The submission also triggers a $4.5 million milestone payment from Eli Lilly & Co., which is co-developing the drug in China.